BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND KDM5C, XE169, SMCX, JARID1C, 8242, ENSG00000126012, DXS1272E, MRXSJ, MRXJ, RP11-258C19_2
90277 results:

  • 1. Deciphering the progression of fine-needle aspiration: A bibliometric analysis of thyroid nodule research.
    Liu T; Yang F; Qiao J; Mao M
    Medicine (Baltimore); 2024 May; 103(20):e38059. PubMed ID: 38758913
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid cancer.
    Fu G; Chazen RS; MacMillan C; Witterick IJ
    JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
    Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
    Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
    Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
    Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
    J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
    Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
    BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
    JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Rare Columnar Cell Variant of Papillary Thyroid Carcinoma with Cervical Spine Metastasis: A Case Report.
    Yu J; Yang G; Oh HY; Ryu YJ
    Curr Med Imaging; 2024; 20(1):e15734056300884. PubMed ID: 38752631
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Trends and projections of the global burden of thyroid cancer from 1990 to 2030.
    Hu S; Wu X; Jiang H
    J Glob Health; 2024 May; 14():04084. PubMed ID: 38751316
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.
    Shi X; Guo S; Duan Q; Zhang W; Gao S; Jing W; Jiang G; Kong X; Li P; Li Y; Teng C; Xu X; Chen S; Nian B; Li Z; Zhong C; Yang X; Zhu G; Du Y; Zhang D; Jin G
    J Exp Clin Cancer Res; 2024 May; 43(1):145. PubMed ID: 38750539
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Non-specific uptake of
    Li Y; Gao J; Li Y; Duan X; Shen C
    Sci Rep; 2024 May; 14(1):11141. PubMed ID: 38750103
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Feasibility and complications after transoral endoscopic thyroidectomy via vestibular approach (TOETVA) - a single-center first experience case series.
    Kinet S; van Weezelenburg MAS; Pijnenburg A; Stoot JHMB; van Bastelaar J
    Langenbecks Arch Surg; 2024 May; 409(1):158. PubMed ID: 38748236
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
    Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
    Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [The clinicopathological features of adult thyroid tumors with DICER1 mutation].
    Tang J; Huang JJ; Luo YL; Zhang LK; Wang QQ; Chen J; Liu ZY
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1623-1627. PubMed ID: 38742350
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.
    Kim BG; Lee SH; Jang Y; Kang S; Kang CM; Cho NH
    J Transl Med; 2024 May; 22(1):453. PubMed ID: 38741142
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles.
    Lomphithak T; Sae-Fung A; Sprio S; Tampieri A; Jitkaew S; Fadeel B
    Nanomedicine; 2024 Jan; 55():102714. PubMed ID: 38738528
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Blood Lead Level as Marker of Increased Risk of Ovarian cancer in BRCA1 Carriers.
    Kiljańczyk A; Matuszczak M; Marciniak W; Derkacz R; Stempa K; Baszuk P; Bryśkiewicz M; Lubiński K; Cybulski C; Dębniak T; Gronwald J; Huzarski T; Lener MR; Jakubowska A; Szwiec M; Stawicka-Niełacna M; Godlewski D; Prusaczyk A; Jasiewicz A; Kluz T; Tomiczek-Szwiec J; Kilar-Kobierzycka E; Siołek M; Wiśniowski R; Posmyk R; Jarkiewicz-Tretyn J; Sun P; Scott RJ; Narod SA; Lubiński J
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732616
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The Role of Glutathione Transferase Omega-Class Variant Alleles in Individual Susceptibility to Ovarian cancer.
    Simic P; Coric V; Pljesa I; Savic-Radojevic A; Zecevic N; Kocic J; Simic T; Pazin V; Pljesa-Ercegovac M
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732205
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4514.